These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 1857487)

  • 1. The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
    Hirano T; Mamo JC; Nagano S; Sugisaki T
    Nephron; 1991; 58(1):95-100. PubMed ID: 1857487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis.
    Hirano T; Morohoshi T
    Nephron; 1992; 60(4):443-7. PubMed ID: 1584321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hyperlipidemia with probucol reduces proteinuria in puromycin aminonucleoside-induced nephrotic rats.
    Hirano T; Mamo JC; Ohnami K; Sugisaki T
    Nephron; 1990; 54(4):358-9. PubMed ID: 2325806
    [No Abstract]   [Full Text] [Related]  

  • 4. Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome.
    Drukker A; Eddy AA
    J Am Soc Nephrol; 1998 Feb; 9(2):243-51. PubMed ID: 9527400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine.
    Shafrir E
    Isr J Med Sci; 1996 Jun; 32(6):390-7. PubMed ID: 8682644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND; Liang KH
    Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant.
    Magil A
    J Am Soc Nephrol; 1996 Nov; 7(11):2340-7. PubMed ID: 8959623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study.
    Querfeld U; Kohl B; Fiehn W; Minor T; Michalk D; Schärer K; Müller-Wiefel DE
    Pediatr Nephrol; 1999 Jan; 13(1):7-12. PubMed ID: 10100282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
    Iida H; Izumino K; Asaka M; Fujita M; Nishino A; Sasayama S
    Nephron; 1987; 47(4):280-3. PubMed ID: 3696330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High density lipoproteinuria in nephrotic syndrome.
    de Mendoza SG; Kashyap ML; Chen CY; Lutmer RF
    Metabolism; 1976 Oct; 25(10):1143-9. PubMed ID: 184367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats.
    Moritomo Y; Hirano T; Ebara T; Kurokawa M; Naito H; Furukawa S; Nagano S
    Nephron; 1994; 67(2):218-25. PubMed ID: 8072613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
    Hirano T; Komuro F; Furukawa S; Nagano S; Takahashi T
    Metabolism; 1990 Jun; 39(6):605-9. PubMed ID: 2112675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catabolic defect of triglyceride is associated with abnormal very-low-density lipoprotein in experimental nephrosis.
    Furukawa S; Hirano T; Mamo JC; Nagano S; Takahashi T
    Metabolism; 1990 Jan; 39(1):101-7. PubMed ID: 2294370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.
    Gherardi E; Calandra S
    Biochim Biophys Acta; 1982 Feb; 710(2):188-96. PubMed ID: 7066357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis.
    Lee HS; Jeong JY; Kim BC; Kim YS; Zhang YZ; Chung HK
    Kidney Int; 1997 Apr; 51(4):1151-9. PubMed ID: 9083281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
    Yamashita J; Nakajima K; Ohno Y; Kaneshiro Y; Matsuo T; Tanaka H; Kaneko K
    Eur J Pharmacol; 2008 Jul; 589(1-3):239-44. PubMed ID: 18541230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of plasma lipid levels by plasma viscosity in nephrotic rats.
    Yedgar S; Eilam O; Shafrir E
    Am J Physiol; 1985 Jan; 248(1 Pt 1):E10-4. PubMed ID: 3966545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the lipoprotein lipase activator NO-1886 on adriamycin-induced nephrotic syndrome in rats.
    Nakayama K; Hara T; Kusunoki M; Tsutsumi K; Minami A; Okada K; Sakamoto S; Ohnaka M; Miyata T; Nakamura T; Aoki T; Fukatsu A; Nakaya Y; Kakumu S
    Metabolism; 2000 May; 49(5):588-93. PubMed ID: 10831167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catabolism of very low density lipoproteins in experimental nephrosis.
    Garber DW; Gottlieb BA; Marsh JB; Sparks CE
    J Clin Invest; 1984 Oct; 74(4):1375-83. PubMed ID: 6480830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.
    Valeri A; Gelfand J; Blum C; Appel GB
    Am J Kidney Dis; 1986 Dec; 8(6):388-96. PubMed ID: 3544820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.